Eli Lilly & Co. (LLY) to Charge $2,100 Per Dose of Bebtelovimab Antibody Drug - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eli Lilly & Co. (LLY) Shares Slide After Missing Estimates
August 4, 2022 11:06 AM EDTEli Lilly & Co. (NYSE: LLY) shares are down Thursday following its second-quarter earnings report, which saw it miss analyst estimates.
The drugmaker reported earnings of $1.25 per share, $0.46 below the analyst estimate of $1.71, while revenue came in at $6.49 billion versus the consensus estimate of $6.85... More
